Dear Sirs, T ype 2 diabetes (T2DM) is associated with high cardiovascular mortality. 1 Identifying subsets of T2DM patients at higher cardiovascular risk in order to optimise resource utilisation is therefore an appealing proposition.
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Waist circumference (WC) is a reproducible tool to measure abdominal obesity 2 and an independent risk factor for the development of diabetes and cardiovascular disease (CVD). 3 The International Diabetes Federation (IDF) definition for the diagnosis of metabolic syndrome states that increased WC is a diagnostic prerequisite. 4 Patients with T2DM attending a specialist centre may have their cardiovascular risk assessed and treated according to various guidelines. 5, 6 The benefit of measuring waist circumference in this context, in addition to body mass index (BMI) and other obesity-related cardiometabolic risk factors, remains unclear, however. 3, 7 We analysed retrospectively WC, blood pressure and lipid data from 88 consecutive T2DM patients who attended our specialist multidisciplinary diabetes centre over a three-month period. IDF thresholds were used to identify patients with elevated waist circumference, hypertension, high triglycerides and low levels of low-density lipoprotein (LDL) cholesterol. 4 Data from 51 male patients and 37 females with T2DM were analysed. The median age was 65 years for males (range 24-86 years) and 66 years for females (range 37-80 years). Seventy-three patients (83%) had high WC and also met the IDF definition of having metabolic syndrome. Median duration of diabetes was 11 years for men (range 1-55 years) and 11 years for women (range 1-32 years). Patients with the metabolic syndrome had a significantly longer duration of diabetes (mean 12.5 vs. 12.2 years; median 11 vs. 8 years; p=0.951, Mann-Whitney U test). Sixtyseven patients (76%) had treated hypertension; 18 patients (20%) were normotensive (blood pressure below 130/85 mmHg) but were being treated with antihypertensives. Only three patients (4%) had normal blood pressure without treatment. Seventy-three patients (83%) had raised triglycerides as defined by IDF -above 150 mg/dL (1.7 mmol/L), or were undergoing specific treatment for an abnormal lipid profile. Fifteen patients (17%) had normal triglycerides without specific treatment. Forty patients (45%) had low levels of high-density lipoprotein (HDL) cholesterol, less than 40 mg/dL (1.03 mmol/L) in males and less than 50 mg/dL (1.29 mmol/L) in females, or were taking lipidlowering therapy.
Fourteen (93%) of 15 patients without high WC had low HDL, high triglycerides or hypertension using the same IDF criteria. Although patients with high WC had more associated risk factors (mean 2.35 vs. 1.67, p=0.002; Independent t-test), the predictive value of WC as a marker of additional risk factors was not significant (p=0.170; Fisher's exact test).
Our findings suggest that WC fails to stratify risk in T2DM in a secondary care setting. The number of non-glycaemic risk factors was higher in those with raised waist circumference, but without a significant positive predictive value. In actual practice, this is unlikely to alter clinical management significantly.
A subset of patients treated with cardiometabolic drugs such as rimonabant may require serial measurement of waist circumference. 8 This, in our view, does not justify routine measurement of waist circumference in all patients. Aggressive cardiovascular risk reduction should be the norm in all patients with T2DM, irrespective of their waist circumference.
